What began as a diabetes treatment expanded into one of the fastest-growing drug categories in recent memory. Millions of patients now depend on GLP-1 medicines for weight management and metabolic health.
Behind the sales numbers sits a significant problem, though. The plants needed to produce these peptide molecules take years to catch up with real-world demand. That gap leaves ripple effects that most companies still haven’t planned around.
Understanding that capacity crunch, and what pharma leaders should be doing differently, matters for anyone bringing a peptide drug to market next.
Why Is GLP-1 Demand Outpacing Global Manufacturing Capacity?
That gap traces back to two forces moving at different speeds. Patient demand for GLP-1 drugs accelerated within just a few years. Manufacturing capacity takes far longer to build than that. A short string of major approvals drove most of this acceleration:
- Semaglutide received FDA approval for chronic weight management in June 2021
- Tirzepatide received FDA approval for chronic weight management in November 2023
Each approval opened GLP-1 drugs to a far larger patient population than earlier forecasts expected. Tirzepatide’s approval added a second high-volume product competing for the same limited production lines.
Europe and Japan cleared these drugs on their own separate timelines. That staggered rollout added pressure in stages, rather than all at once.
Few executives expected a diabetes drug to become a mainstream weight-loss treatment this quickly. Fewer still had budgeted manufacturing capacity for that shift.
Peptide production lines need years of lead time to prepare for a surge like this. That’s exactly the kind of planning a peptide CDMO has to get right years before demand arrives. That mismatch shows up clearly in national data. The Centers for Disease Control and Prevention tracked this shift directly. GLP-1 use among American adults with diabetes rose from 7.6% in 2018 to 26.5% in 2024. Few facilities were built to handle a jump that size. The result is a structural gap between what patients need and what facilities can produce.
What Makes Peptide CDMO Capacity So Difficult to Scale Quickly?
Peptide manufacturing doesn’t scale the way small-molecule production does, which is why this capacity shortfall takes years to close. A regular pharmaceutical plant can’t simply switch over to peptide chemistry overnight. A peptide CDMO needs equipment and facilities built specifically for this work. Putting that infrastructure in place takes real time. Here’s what usually goes into it:
- Reactors and purification systems built specifically for peptide chemistry
- Cleanroom facilities that most general-purpose plants don’t already have
- Dozens of production and purification steps for each peptide batch
- 2 to 3 years to design and validate a new facility before it can supply commercial orders
That timeline explains why only a handful of established manufacturers hold most of the world’s peptide capacity today.
When one client’s needs change, every other program sharing that same production line feels the effect. This is why choosing the right peptide CDMO partner early matters more for peptide programs than for typical small-molecule projects.
Companies with access to flexible, multi-facility capacity can absorb sudden demand shifts better than those relying on a single site. Because of this, booking capacity a year or two before a planned launch has become standard practice across the industry.
Which Other Drug Programs Are Competing for the Same Peptide CDMO Capacity?
GLP-1 drugs aren’t the only programs competing for peptide manufacturing capacity. Cancer treatments built on peptide-drug conjugates need the same specialized production lines. So do treatments for rare metabolic diseases.
All three types of programs compete for the same limited pool of reactors. When a peptide CDMO commits capacity to a large GLP-1 contract, smaller programs often wait longer for open slots. That wait creates a real disadvantage for biotech companies working outside the metabolic disease space.
Their timelines now depend on the capacity that bigger commercial contracts increasingly absorb. Manufacturing cost remains part of the problem, too. Research indexed by the National Institutes of Health identifies cost as a limiting factor in scaling peptide production. That holds true even though the underlying chemistry is well understood.
Together, these pressures have made planning for peptide CDMOs far more urgent for smaller companies entering clinical trials. Companies without established manufacturing relationships face the steepest climb. Those with reserved capacity stay closer to their original launch timelines.
What Are Pharma and Biotech Companies Still Not Planning For?
Despite this history, many pharma and biotech companies still don’t plan for capacity risk. Most development teams are used to sourcing small-molecule drugs, where finding manufacturing capacity is rarely hard. Peptide programs don’t work the same way. Teams often expect that same easy timeline. The trouble shows up later, once a launch date is already fixed. Here are the specific things most companies fail to plan for:
- Locking in peptide CDMO capacity early, during preclinical work, well before Phase 2 results
- Asking a manufacturing partner directly how busy its production lines already are
- Working with two manufacturing partners instead of one, so a delay at one site doesn’t stop the whole program
- Planning for realistic peptide CDMO production wait times instead of best-case timelines that rarely happen
- Setting money aside early to reserve production slots, since partners increasingly ask for this upfront
- Building manufacturing plans into the overall drug development plan from the very beginning
Companies that build these peptide CDMO planning habits early tend to hit their commercial launch dates. Those who skip this step usually learn the cost mid-trial. By then, the launch date is already public and hard to move. They end up renegotiating capacity terms with far less leverage.
Neuland Laboratories, a peptide CDMO, is one example of this kind of planning in practice. The company is bringing a dedicated peptide facility, ahead of anticipated demand. Companies exploring peptide development can contact Neuland Laboratories today to discuss capacity planning for upcoming programs.
FAQs
- What is the difference between a peptide CDMO and a peptide CMO?
A peptide CMO manufactures peptide APIs to specifications that a company has already finalized. A peptide CDMO also handles the process development needed to reach that specification. A CDMO typically adds:
- Route scouting and process development
- Regulatory filing support
- A path from development batches to commercial supply
Most new peptide programs benefit more from a CDMO.
- How should pharma and biotech companies evaluate a peptide CDMO before signing?
Evaluating a peptide CDMO goes beyond checking open reactor time. Look past headline capacity numbers at:
- Track record with your peptide class
- In-house analytical capability
- Regulatory filing history in your target markets
Reactor space changes month to month. A CDMO’s technical depth and regulatory record don’t.
- What drives the cost of working with a peptide CDMO?
Peptide API costs are far higher than those of small-molecule APIs. Purification often accounts for the largest cost component. Sequence length and batch size matter too, since smaller clinical batches cost more per gram than commercial runs. Efficient purification technology can bring costs down meaningfully.
- How long does it take a peptide CDMO to move a molecule from development to commercial supply?
Timelines vary, but process development and route optimization usually take twelve to eighteen months. Technology transfer and scale-up add several more months, plus time for regulatory filings. Altogether, development to a commercial-scale peptide supply typically takes two to four years, faster with a single CDMO throughout.
